Changes in hepatitis C virus genotype distribution in Japan.
about
Daclatasvir and asunaprevir treatment in patients with severe liver fibrosis by HCV genotype 1b infection: Real world data.Genotype-Associated Differential NKG2D Expression on CD56+CD3+ Lymphocytes Predicts Response to Pegylated-Interferon/Ribavirin Therapy in Chronic Hepatitis C.Geographic distribution of HCV genotypes in Libya and analysis of risk factors involved in their transmissionRapid Increase in Serum Low-Density Lipoprotein Cholesterol Concentration during Hepatitis C Interferon-Free TreatmentSimeprevir for the treatment of hepatitis C virus infection.Randomized Phase 3 Trial of Ombitasvir/Paritaprevir/Ritonavir and Ribavirin for Hepatitis C Virus Genotype 2-Infected Japanese Patients.In vitro and in vivo antiviral activity and resistance profile of ombitasvir, an inhibitor of hepatitis C virus NS5A.Population Pharmacokinetics of Paritaprevir, Ombitasvir, and Ritonavir in Japanese Patients with Hepatitis C Virus Genotype 1b Infection.Resistance Characterization of Hepatitis C Virus Genotype 2 from Japanese Patients Treated with Ombitasvir and Paritaprevir/Ritonavir.Epidemiologic features of 348 children with hepatitis C virus infection over a 30-year period: a nationwide survey in Japan.Predictors of treatment efficacy and ALT non-normalization with sofosbuvir/ribavirin therapy for patients with hepatitis C virus genotype 2.In vitro activity and resistance profile of dasabuvir, a nonnucleoside hepatitis C virus polymerase inhibitor.Sofosbuvir plus ribavirin in Japanese patients with chronic genotype 2 HCV infection: an open-label, phase 3 trial.Pilot study for hepatitis virus screening among employees and effective approach to encourage screened positive employees to receive medical care in Japan.Short-term risk of hepatocellular carcinoma after hepatitis C virus eradication following direct-acting anti-viral treatment.Integrated Resistance Analysis of CERTAIN-1 and CERTAIN-2 Studies in Hepatitis C Virus-Infected Patients Receiving Glecaprevir and Pibrentasvir in Japan.Current characteristics of hemophilia patients co-infected with HIV/HCV in Japan.Systematic overview of hepatitis C infection in the Middle East and North Africa
P2860
Q31170657-F4FBFBF6-16E5-4BA1-8A69-A9CAD7BAA7BBQ35597464-092EB7A3-564B-4247-B9BD-CBF41696D000Q35751678-BA5F1710-1F6E-4ABA-9797-035F3A0C61B5Q36146807-4C0B26AE-503B-4BF4-910D-88E220E8578FQ38247985-6929AED5-DC4F-4269-ADFA-166CD1770141Q38376454-D2A619EE-B3FB-45B4-9ADA-913F939C8B9CQ38934649-1684AD11-C47E-420D-9954-588823A5E7D2Q39675766-1BC0C8C5-33F6-4515-9434-5A23ED5212CDQ40069650-54EDA851-A67C-4EFA-8E8B-CAFC0703A620Q40178123-BCA764FB-4DAB-49C6-B87F-D9017B47D75EQ40343824-46B62967-C13D-408D-B72B-9D17450702E6Q41585354-AD99A6EB-FFF0-474F-BBF5-44EF95DAD4B8Q41750256-88AF539D-1605-4A24-B655-28448241B2F6Q41928083-8DDE3204-8344-419F-9340-DF233AEEA8F2Q45326298-EEE3C6B9-7E08-4608-AD91-FA37E80B8FE5Q47572297-B7A1D238-8398-48C1-9658-A6CBEC741CB2Q49727776-AC717417-1199-48E4-BD98-4A2112528EF4Q56924599-14BB67CF-D8FE-4F7D-A7DC-080F0FFBFC16
P2860
Changes in hepatitis C virus genotype distribution in Japan.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
2014年论文
@zh
2014年论文
@zh-cn
name
Changes in hepatitis C virus genotype distribution in Japan.
@en
Changes in hepatitis C virus genotype distribution in Japan.
@nl
type
label
Changes in hepatitis C virus genotype distribution in Japan.
@en
Changes in hepatitis C virus genotype distribution in Japan.
@nl
prefLabel
Changes in hepatitis C virus genotype distribution in Japan.
@en
Changes in hepatitis C virus genotype distribution in Japan.
@nl
P2093
P2860
P1476
Changes in hepatitis C virus genotype distribution in Japan.
@en
P2093
P2860
P304
P356
10.1017/S0950268814000478
P50
P577
2014-03-05T00:00:00Z